Table 1.

Baseline characteristics of 21 clinical trials included in the meta-analysis (Part 2)

Author	Clinical register	Year	Subgroup	Clinical status	Treatment	Patient states	Age (years), median (range)	Size
Alvarado Y12	NA	2014	Multiple types	NA	Monotherapy	Prior treatments	54 (18–87)	69
Cooper TM13	NCT01411267	2016	Quizartinib	Phase I	Chemotherapy, quizartinib	Relapsed AML	≤21	14
Cortes JE30	NA	2012	Quizartinib	Phase II	Monotherapy	Relapsed/refractory AML	≥60	133
Cortes JE14	NCT00462761	2013	Quizartinib	Phase I	Monotherapy	Relapsed/refractory AML	60 (23–86)	54
Crump M15	NA	2010	Sorafenib	Phase I	Monotherapy	Relapsed/refractory AML or MDS	71 (37–82)	27
Fiedler W17	NA	2005	Sunitinib	Phase I	Monotherapy	Relapsed/refractory AML	72 (54–80)	12
Fiedler W16	NCT00783653	2015	Sunitinib	Phase I/II	Chemotherapy, sunitinib	Untreated newly diagnosed AML	≥60	22
Fischer T18,a	NCT00045942	2010	Midostaurin	Phase IIB	Monotherapy	Relapsed/refractory AML or MDS	≥18	92
Inaba H19	NA	2011	Sorafenib	Phase I	Sorafenib, clofarabine, and cytarabine	Relapsed/refractory AML	≤21	11
Knapper S20	NA	2006	Lestaurtinib	Phase II	Monotherapy	Untreated AML	73 (67–82)	27
Levis MJ29	NA	2012	Quizartinib	Phase II	Monotherapy	Relapsed/refractory AML	FLT3–ITD (+): 50 (19–77) FLT3–ITD (−): 55 (30–73)	137
Macdonald DA21	IND.186	2013	Sorafenib	Phase I/II	Sorafenib and low-dose cytarabine	No prior chemotherapy	≥60	21
Pratz KW11	NA	2010	Sorafenib	N	Monotherapy	Relapsed/refractory AML	Median 63	12
Ramsingh G22	NCT01161550	2014	Midostaurin	Phase I	Chemotherapy and midostaurin	Relapsed/refractory AML	52 (32–71)	9
Ravandi F24,b	NA	2010	Sorafenib	Phase I/II	Sorafenib, idarubicin, and cytarabine	Untreated AML	≤65	51
Ravandi F23	NA	2014	Sorafenib	Phase II	Sorafenib, cytarabine, and idarubicin	Untreated AML	53 (18–66)	62
Stone RM26,c	NA	2012	Midostaurin	Phase IB	Midostaurin, chemotherapy	Untreated AML	Median 48.5	40
Walker AR28,d	NCT01174888	2016	Midostaurin	Phase I	Midostaurin, bortezomib, and MEC	Relapsed/refractory AML	19–70	23
Röllig C25	NA	2012	Sorafenib	NA	Mixed	Mixed	64.5 (19–82)	28
Iyer SP31	NA	2016	Crenolanib	NA	Crenolanib, salvage chemotherapy, and HAM	Prior treatments	70.5 (22–90)	6
Zhang W27	CTEP25XS06801	2008	Sorafenib	NA	Monotherapy	Prior treatments	61.5 (48–81)	16

Notes:

^aORR=CR+PR+HI+BR defined in this article.

^bOnly patients in Phase II included.

^cOnly patients in dose schedule III included.

^dOnly patients in dose levels 3, 3^*, 3A, and 4 included.

Abbreviations: NA, not available; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; MEC, mitoxantrone, etoposide, cytarabine; HAM, high-dose Ara-C/mitoxantrone.